Prostate Cancer

Prostate Cancer: treatments, trials & survival

Prostate cancer is the most common cancer in men. Discover treatment options from active surveillance to advanced therapies and ongoing clinical trials.

New Cases (2024)
299,010
5-Yr Survival
97.1%
Annual Deaths
35,250
Trend
Increasing
See active trials

About Prostate Cancer

Prostate cancer is the most common cancer in men. Discover treatment options from active surveillance to advanced therapies and ongoing clinical trials.

According to the National Cancer Institute’s SEER database, an estimated 299,010 new cases of prostate cancer will be diagnosed in the United States in 2024, with approximately 35,250 deaths. The overall 5-year relative survival rate is 97.1%.

Source: NCI SEER Data: 1975–2022

Treatment options

Current treatment approaches for prostate cancer depend on the stage at diagnosis, tumor characteristics, and the patient’s overall health. The most common options include:

1
Active Surveillance
2
Surgery (Prostatectomy)
3
Radiation Therapy
4
Hormone Therapy (ADT)
5
Chemotherapy
6
PARP Inhibitors
7
Immunotherapy

Treatment recommendations should always be discussed with a qualified oncologist. The options listed above are based on current clinical guidelines and may vary case by case.

Stages

Staging describes the extent of cancer in the body and is crucial for planning the most appropriate treatment:

Stage I Stage II Stage III Stage IV

Known risk factors

Understanding risk factors can support prevention and early detection. Known risk factors for this cancer include:

Age (over 50)
African American race
Family history
BRCA2 gene mutations
Obesity
Diet high in processed meat

Not sure where to start?

A patient navigator familiar with prostate cancer can help you understand your options and connect you with top US hospitals. Free & confidential.

Active clinical trials

Clinical trials offer access to cutting-edge treatments not yet widely available. The trials below are sourced in real time from ClinicalTrials.gov:

Frequently asked questions

Prostate cancer has one of the highest survival rates: the 5-year relative survival rate is 97.1%. For localized and regional stages, survival approaches nearly 100%.
Active surveillance is recommended for low-risk, early-stage prostate cancer with Gleason scores of 6 or below. It involves regular PSA tests, digital rectal exams, and periodic biopsies.
PARP inhibitors like olaparib and rucaparib are targeted therapies for metastatic prostate cancer with BRCA or other DNA repair gene mutations. They block cancer cells from repairing their DNA.
The Prostate-Specific Antigen (PSA) test measures PSA levels in the blood. Elevated levels may indicate prostate cancer, though other conditions can also raise PSA levels.
You’re not alone

Looking for prostate cancer treatment options?

A patient navigator can help you explore treatment pathways, find clinical trials near you, and connect with specialists who see prostate cancer every day. Free, confidential consultation.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.